NASDAQ:BABY - Natus Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.18 +0.99 (+3.93 %)
(As of 04/26/2019 09:49 AM ET)
Previous Close$25.19
Today's Range$24.73 - $26.4950
52-Week Range$23.58 - $37.95
Volume35,057 shs
Average Volume376,249 shs
Market Capitalization$888.97 million
P/E Ratio18.44
Dividend YieldN/A
Beta0.52
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Receive BABY News and Ratings via Email

Sign-up to receive the latest news and ratings for BABY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:BABY
CUSIP63905010
Phone925-223-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$530.89 million
Cash Flow$3.0266 per share
Book Value$11.80 per share

Profitability

Net Income$-22,930,000.00

Miscellaneous

Employees1,729
Market Cap$888.97 million
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Natus Medical (NASDAQ:BABY) Frequently Asked Questions

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How will Natus Medical's stock buyback program work?

Natus Medical declared that its Board of Directors has initiated a stock repurchase plan on Thursday, February 22nd 2018, which authorizes the company to repurchase $30,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its stock is undervalued.

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) posted its earnings results on Thursday, April, 25th. The medical equipment provider reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The medical equipment provider had revenue of $114.80 million for the quarter, compared to analyst estimates of $113.30 million. Natus Medical had a positive return on equity of 11.64% and a negative net margin of 4.32%. The business's revenue was down 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.24 earnings per share. View Natus Medical's Earnings History.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $1.17-1.44 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.28. The company issued revenue guidance of $498.90 million, compared to the consensus revenue estimate of prior $1.12-1.49.Natus Medical also updated its Q2 guidance to $0.25-0.32 EPS.

What price target have analysts set for BABY?

2 Wall Street analysts have issued 1 year target prices for Natus Medical's shares. Their predictions range from $36.00 to $36.00. On average, they expect Natus Medical's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price. View Analyst Price Targets for Natus Medical.

What is the consensus analysts' recommendation for Natus Medical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natus Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natus Medical.

Has Natus Medical been receiving favorable news coverage?

News headlines about BABY stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Natus Medical earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.

Who are some of Natus Medical's key competitors?

What other stocks do shareholders of Natus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natus Medical investors own include Intel (INTC), Activision Blizzard (ATVI), Gilead Sciences (GILD), Starbucks (SBUX), Walt Disney (DIS), Alphabet (GOOG), NVIDIA (NVDA), Skyworks Solutions (SWKS), Tesla (TSLA) and Celgene (CELG).

Who are Natus Medical's key executives?

Natus Medical's management team includes the folowing people:
  • Mr. Jonathan A. Kennedy CPA, Pres, CEO & Director (Age 48)
  • Dr. D. Christopher Chung, VP of Quality, Regulatory Affairs & Chief Medical Officer (Age 55)
  • Mr. Austin F. Noll III, Exec. VP & Chief Commercial Officer (Age 52)
  • Mr. Benjamin Drew Davies, Exec. VP & CFO (Age 53)
  • Mr. Seán Langan, VP Global Operations

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fenimore Asset Management Inc. (1.16%), Confluence Investment Management LLC (0.96%), Clean Yield Group (0.05%), BNP Paribas Arbitrage SA (0.02%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Lisa Wipperman Heine, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Which major investors are selling Natus Medical stock?

BABY stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, BNP Paribas Arbitrage SA and Clean Yield Group. Company insiders that have sold Natus Medical company stock in the last year include Dong Chune Christopher Chung, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical.

Which major investors are buying Natus Medical stock?

BABY stock was purchased by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc. and Meeder Asset Management Inc.. Company insiders that have bought Natus Medical stock in the last two years include James B Hawkins and Lisa Wipperman Heine. View Insider Buying and Selling for Natus Medical.

How do I buy shares of Natus Medical?

Shares of BABY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natus Medical's stock price today?

One share of BABY stock can currently be purchased for approximately $26.18.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $888.97 million and generates $530.89 million in revenue each year. The medical equipment provider earns $-22,930,000.00 in net income (profit) each year or $1.42 on an earnings per share basis. Natus Medical employs 1,729 workers across the globe.

What is Natus Medical's official website?

The official website for Natus Medical is http://www.natus.com.

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The medical equipment provider can be reached via phone at 925-223-6700 or via email at [email protected]


MarketBeat Community Rating for Natus Medical (NASDAQ BABY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Natus Medical and other stocks. Vote "Outperform" if you believe BABY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BABY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Featured Article: Trading Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel